Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Down 23.0% in December

Delcath Systems, Inc. (NASDAQ:DCTH) was the recipient of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 1,040,000 shares, a decrease of 23.0% from the December 15th total of 1,350,000 shares. Based on an average daily trading volume, of 386,900 shares, the short-interest ratio is presently 2.7 days.

Delcath Systems Trading Up 0.2 %

Shares of Delcath Systems stock opened at $12.71 on Thursday. The company’s 50-day moving average price is $11.33 and its 200-day moving average price is $9.83. Delcath Systems has a 12-month low of $3.70 and a 12-month high of $13.30. The company has a market cap of $406.39 million, a price-to-earnings ratio of -9.41 and a beta of 0.87.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on DCTH. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Delcath Systems in a report on Tuesday. Canaccord Genuity Group reiterated a “buy” rating and issued a $21.00 target price on shares of Delcath Systems in a research note on Friday, October 18th. Stephens restated a “buy” rating on shares of Delcath Systems in a research note on Friday, October 18th. Finally, StockNews.com raised shares of Delcath Systems from a “sell” rating to a “hold” rating in a report on Friday, October 25th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $21.50.

Institutional Trading of Delcath Systems

Several institutional investors and hedge funds have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Delcath Systems in the third quarter worth $102,000. Barclays PLC bought a new stake in shares of Delcath Systems during the 3rd quarter valued at about $104,000. Jane Street Group LLC purchased a new position in shares of Delcath Systems during the third quarter worth about $110,000. Riverwater Partners LLC bought a new position in shares of Delcath Systems in the third quarter worth approximately $161,000. Finally, Virtu Financial LLC bought a new stake in Delcath Systems during the third quarter valued at approximately $289,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.